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Key summary:  In our national cohort of Veterans with initial mild Clostridium difficile infection (CDI) and treated 
with metronidazole, age < 65 years was the only predictor of success 30-days post treatment (absence of 
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mortality or recurrence).  Among these younger patients with mild CDI, success rates were similar with 
metronidazole and vancomycin. 
 
Brief 40-word summary:  Age < 65 years was predictive of success (absence of mortality or recurrence 30 
days post-treatment) among Veterans with initial mild Clostridium difficile infection treated with metronidazole.  
Among patients aged <65 years, success rates were similar with metronidazole and vancomycin. 
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ABSTRACT   
Background: Metronidazole may still be an appropriate therapeutic option for mild Clostridium difficile infection 
(CDI) in select patients, but data is limited to guide clinicians in identifying these patients. 
 
Methods: Our two-stage study included a national cohort of Veterans with a first episode of mild CDI (2010-
2014). First, among those treated with metronidazole, we identified predictors of success, defined as absence 
of all-cause mortality or recurrence 30-days post-treatment, using multivariable unconditional logistic regression.  
Second, among a subgroup of patients with characteristic/s predictive of success identified in the first-stage, we 
compared clinical outcomes among those treated with metronidazole compared with vancomycin, using Cox 
proportional hazards models for time to 30-day all-cause mortality, CDI recurrence, and failure. 
 
Results:  Among 3,656 patients treated with metronidazole, we identified 3,282 patients with success and 374 
patients without success (failure). Younger age was the only independent predictor of success. Age <65 years 
was associated with an odds of success 1.63 times higher (95% confidence interval [CI] 1.29 – 2.06) than age 
>65 years.  Among 115 propensity-score matched pairs <65 years of age, no significant differences were 
observed between metronidazole and vancomycin (reference) for all-cause mortality (hazard ratio [HR] 0.29, 
95% CI 0.06-1.38), CDI recurrence (HR 0.62, 95% CI 0.26-1.49), or failure (HR 0.50, 95% CI 0.23-1.07). 
 
Conclusion: Among patients <65 years of age with initial mild CDI, clinical outcomes were similar with 
metronidazole and vancomycin.  These data suggest metronidazole may be considered for the treatment of initial 
mild CDI among patients 65 years of age or younger.    
  
 5 
Word count: 2,989 
BACKGROUND  
Clostridium difficile has become the most common cause of healthcare associated infections in the United 
States.[1]  For over three decades metronidazole has been the mainstay of treatment for initial cases of mild to 
moderate Clostridium difficile infection (CDI).[2]  Until recently, metronidazole was recommended as the first-line 
treatment option over vancomycin for initial cases of mild-moderate CDI.[2, 3]  In early 2018, updated clinical 
practice guidelines from the Infectious Diseases Society of America (IDSA) and the Society for Healthcare 
Epidemiology of America (SHEA) were released, which no longer recommend metronidazole for initial non-
severe CDI as per previous guidelines from 2010.[2, 3]  Updated guidelines only distinguish severe disease from 
non-severe disease (previously defined as mild-moderate disease), and 2010 guidelines do not distinguish 
between mild and moderate disease.[2, 3]    
 
This substantial change in non-severe CDI treatment recommendations is largely based off evidence 
demonstrating better outcomes associated with vancomycin as compared to metronidazole in patients with 
severe CDI.[4, 5]  Among patients with mild CDI, several studies have demonstrated no difference between 
vancomycin and metronidazole for mortality, CDI recurrence or clinical cure.[4-6]  When metronidazole is used 
per 2010 CDI guidelines in certain patients with mild-moderate disease it may still have similar effectiveness to 
vancomycin.  Metronidazole is less expensive and may be associated with lower colonization and/ or 
development of drug-resistant organisms compared with vancomycin.[7, 8] 
 
Since publication of the updated guidelines, expert correspondence has recommended continued consideration 
of metronidazole as a first-line option for patients with mild CDI and a low risk for disease complications.[8]  
Limited data exists to guide clinicians in identifying in which patients metronidazole may still be used.  As such, 
first we sought to identify independent predictors of success (defined as absence of mortality or recurrence) 
among a national cohort of Veterans with mild CDI treated with metronidazole per 2010 CDI guideline 
recommendations.  Then, we sought to compare the effectiveness of metronidazole with vancomycin in patients 
with mild CDI.  Characteristics associated with success were used to identify the subgroup for our comparative 
effectiveness analysis. 
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METHODS 
Study Population 
A cohort of Veterans with a first CDI episode (defined as a stool sample positive for C. difficile toxin(s) and > 2 
days of CDI treatment) from May 1, 2010 to December 30, 2014 was used.[9]  CDI episodes from inpatient and 
outpatient settings from 125 VA centers nationally were included.  Only patients with mild disease (defined as a 
white blood cell count (WBC) <15 x 103/μL and a serum creatinine (SCr) was <1.5 mg/dL within 7 days of CDI 
treatment) and those treated per guidelines (10-14 days of monotherapy with oral metronidazole or oral 
vancomycin) were included.[2]  Patients with missing WBC or SCr were excluded.  
 
Study Design 
We conducted a two-stage analysis among our large national cohort of Veterans with mild CDI, first conducting 
a predictive analysis and second a comparative effectiveness analysis. 
 
Predictive Analysis. 
We compared patients with and without successful outcomes with a mild first CDI episode treated with 
metronidazole monotherapy.  Patients with success were those who did not die or have a CDI recurrence at day 
30, and patients without success were those who died or had a CDI recurrence within 30 days post-treatment 
(failures).  CDI recurrence was defined as another CDI positive stool sample or CDI diagnosis code (008.45) and 
at least two days of subsequent CDI treatment at least 14 days after the initial positive stool sample and within 
30 days post-treatment of the initial episode. Our a priori definition of recurrence was a subsequent episode 
within 30 days post-treatment, as recurrence risk is greatest within 10 days post-treatment and in clinical trials 
recurrence is commonly defined within 28-30 days post-treatment.[10, 11] 
 
Predictors assessed are presented in Table 1.  Treatment setting (acute, long-term care, or outpatient) was 
defined based on patient location at the time of positive stool sample.  Comorbidities were identified using 
International Classification of Diseases, 9th Revision (ICD-9) diagnosis and procedure codes within the one year 
prior to the first CDI episode or during treatment.  The Clinical Classifications Software of the Agency for 
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Healthcare Research and Quality and previously described disease categorizations were used to group specific 
diagnoses and procedures into broader disease state groups.[12, 13]  ICD-9 codes were also used to identify 
previous and current infections and other acute events.  Comorbidity burden was assessed using Charlson 
comorbidity index and Elixhauser score.  All medication exposures were defined as binary variables and windows 
of exposure were selected based on clinical relevance or previous work.[14-16]  Inpatient and outpatient 
pharmacy data were utilized to determine all medication exposures and CDI treatment duration.  Hypervirulent 
strain was defined as presence of NAP1/027 where strain type data was available and not hypervirulent/unknown 
strain in the absence hypervirulent strain type or where strain type was missing. Overall, 45 potential predictors 
were selected a priori and assessed.[2, 14, 17-19]    
 
Comparative Effectiveness Analysis. 
In the second phase of our study, we conducted a comparative effectiveness analysis of metronidazole versus 
vancomycin on outcomes among Veterans in a select subgroup of our mild CDI cohort.  We used characteristic/s 
predictive of success with metronidazole identified in the first stage of our study, to select the subgroup to 
compare clinical outcomes with metronidazole and vancomycin.  The primary exposure of interest was CDI 
treatment (metronidazole or vancomycin).  The outcomes of interest were 30-day all-cause mortality, 30-day CDI 
recurrence, and a composite failure outcome (lack of success as defined above).  Numerous covariates, which 
may confound the association between CDI treatment and poor clinical outcomes in patients with CDI, were 
identified and measured a priori based on underlying causal beliefs.[2, 14, 17-19]   
 
Statistical Analysis 
Predictive Analysis. 
We used backwards, manual, stepwise unconditional logistic regression to identify independent predictors of 
success among patients with a mild first CDI episode treated with metronidazole.[20]  Variables from univariate 
analysis with a p-value of <0.10 were included in subsequent multivariable analysis and removed one-by-one 
from the multivariable model until all remaining variables had a p-value <0.05.[20]  Tolerance and variance 
inflation were used to confirm the absence of collinearity between potential predictors.[20]   
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Comparative Effectiveness Analysis. 
Propensity-score matched Cox proportional hazards models were used to quantify the effect of vancomycin 
versus metronidazole on time to 30-day all-cause mortality, CDI recurrence, and failure among a subgroup of 
patients with characteristic/s associated with metronidazole success.[21]  Propensity scores were developed for 
exposure to metronidazole compared with vancomycin as function of all potential confounders which was 
modeled using logistic regression.[21]  The predicted probability of exposure for each patient (propensity score) 
was estimated using this model.  We assessed common support (overlapping distributions of the propensity 
score between exposure groups) using visual comparison.[21, 22]  We performed nearest-neighbor 1:1 
propensity score matching within 0.01 caliper.  To assess balance of potential confounders, standardized biases 
(absolute standardized difference in means) were examined for the original and matched samples.[22] Crude 
and matched hazard ratios were calculated using Cox proportional hazard regression models.  Cox proportional 
hazard regression proportionality assumptions were assessed.   
 
RESULTS 
Predictive Analysis. 
Among 3,656 patients with mild CDI and treated with metronidazole, we identified 3,282 patients with success 
at day 30 post-treatment and 374 patients without success (failure).  Several significant differences between 
patients with and without success were observed (Table 1).  In multivariable analysis, younger age was the only 
independent predictor of success identified (Table 2).  The odds of success was 1.63 times (95% confidence 
interval [CI] 1.29 – 2.06) higher among patients 65 years of age or younger as compared to those over 65 years 
of age.  There were several predictors of failure identified (odds ratios <1, Table 2) including: a principle diagnosis 
of CDI, current intestinal infection, current respiratory failure, malignancy, previous hospital or long-term care 
exposure, hypoalbuminemia, body mass index (BMI) > 30 kg/m2, and previous probiotic exposure. 
 
Comparative Effectiveness Analysis. 
For the comparative effectiveness analysis, a mild CDI cohort of younger patients 65 years of age or younger 
was selected.  Predictors of treatment and of failure were included in the propensity score model.  Baseline 
characteristics were well balanced in the propensity score matched cohort (115 matched pairs, Table 3). Among 
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the propensity-score matched cohort, no significant differences were observed between metronidazole and 
vancomycin (reference) for the outcomes assessed (Table 4). 
 
DISCUSSION 
To our knowledge this study is the first to focus specifically on identifying predictors of success and comparing 
treatment options in patients with an initial episode of mild CDI.  This work suggests that metronidazole may still 
be an appropriate treatment option for younger patients with initial mild CDI. 
 
Age was the only predictor of success identified and may be one of the most important factors when considering 
which patients with initial mild disease may still be candidates for metronidazole therapy.  Several factors may 
contribute to the increased risk observed in older patients, such as immunosenescence, decreased functional 
status, and underlying comorbidities.[23]  Previous work has demonstrated that older age is an independent risk 
factor for mortality and recurrence in patients with CDI.[15, 24, 25]  Age 65 years or older was among the 
strongest predictors of all-cause mortality identified in a recent national analysis of adults hospitalized with 
CDI.[25]  A systematic review of 39 studies which assessed the impact of age on treatment failures and 
recurrence, found higher rates of treatment failures and CDI recurrences in older patients aged >65 years as 
compared to younger patients (treatment failure: 24.7% vs. 19.6%; p=0.005; recurrence: 23.4% vs 
19.4%; p=0.003).[26]  For patients with mild disease it may be important to avoid metronidazole treatment in 
older patients, however for younger patients metronidazole may still be an option.  
 
Predictors of failure with metronidazole in mild CDI (odds ratio <1) may indicate patient subgroups where 
metronidazole should be avoided.  Similar to previous findings, a principal diagnosis of CDI (as compared to 
those hospitalized without a principal diagnosis of CDI or outpatients) was identified as a significant predictor of 
failure likely related to CDI severity.[9, 27, 28]  Previous hospital or long-term care exposure was also a predictor 
of poor outcomes.  The association between CDI and exposure to healthcare settings is well recognized.[29, 30]  
Within hospital and long-term care settings, the patients are typically older, have an increased exposure to 
antibiotics and gastric acid suppressants, and environmental exposure to C. difficile spores, thus are at an 
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increased risk for the development of initial and recurrent CDI.[10]  These factors may also contribute to an 
increased risk for severe disease and mortality. 
 
Factors, such as hypoalbuminemia, respiratory failure and intestinal infection, which may be markers of severe 
or complicated disease, were also predictive of failure.  Underlying comorbidities and hypoalbuminemia are 
among the most commonly reported risk factors for poor outcomes.[15]  While not included in the IDSA/SHEA 
definitions for severity, hypoalbuminemia is included in other criteria to define severe disease.[5, 31]  While 
antibiotic use was not identified as an independent predictor in our study, antibiotic use is another frequently 
reported risk factor for poor outcomes in patients with CDI.[15]  Patients with comorbid respiratory failure or 
intestinal infections during a CDI episode may be exposed to non-CDI active antibiotics for these conditions 
during their CDI treatment.  It is also possible an intestinal infection diagnosis may not be due to another infection 
but may be due to CDI symptoms themselves.  Our findings suggest that severe underlying comorbidities and 
other markers of severity in addition to those of the IDSA/SHEA, particularly albumin level, should be considered 
when determining which patients have mild disease that can be treated with metronidazole.[31]  Continued work 
is needed to investigate which severity criteria are most useful in defining mild disease that can be successfully 
treated with metronidazole.     
 
Obesity (BMI > 30 kg/m2) was also identified as a predictor of failure.  Previous work has identified obesity as a 
risk factor for the development of CDI.[30]  There is also evidence that obesity is associated with more severe 
disease.[32]  Among a weighted sample of 22,937 patients with CDI presenting to the emergency department, 
extreme obesity (BMI > 40 kg/m2) was associated with an increased risk of in-hospital mortality.[33]  The 
relationship between obesity, severe disease, and mortality is largely unclear at this time, however in general, 
obesity is associated with increased risk of death compared to normal weight BMI categories.[34]  It may be 
advisable for clinicians to avoid use of metronidazole for mild disease in obese patients.   
 
Among patients 65 years of age or younger, we found no difference between metronidazole and vancomycin for 
the treatment of initial mild CDI.  Existing studies focusing on patients with mild disease are limited.  In a single 
center retrospective analysis of 168 cases of mild to moderate CDI, metronidazole and vancomycin yielded 
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similar recurrence rates (13% vs. 9%, p=0.4), however treatment responses were lower for patients treated with 
metronidazole (82% vs 97%, p=0.002).[35]  When stratified by strain, a difference in treatment response was 
only identified among 83 patients with non-NAP1 CDI (78% metronidazole vs. 98% vancomycin, p=0.007) while 
similar rates were observed among 85 patients with NAP1 CDI (86% metronidazole vs. 97% vancomycin, 
p=0.13).  Another retrospective cohort study was conducted in patients with solid organ transplants who had 
mild to moderate CDI.[36]  Similar to our findings, this study found no difference between metronidazole and 
vancomycin for treatment failure (metronidazole 16% vs. vancomycin 10%, p=0.71), 90-day CDI recurrence 
(metronidazole 14% vs. vancomycin 14%, p=0.99), or 30 day all-cause mortality (0 in both groups).  This was a 
small, single center study of 71 patients with limited power to detect significant differences.  A larger national VA 
study was conducted among 10,137 patients with a first episode of CDI treated in the VA healthcare system 
between 2005-2012 that included non-severe and severe CDI.[6]  This study demonstrated that in the overall 
cohort, not stratified by severity, patients treated with vancomycin had a lower risk of mortality versus 
metronidazole (adjusted RR, 0.86; 95% CI, 0.74 to 0.98) but no difference in the risk of recurrence.[6]  Mortality 
differences observed were largely driven by those with severe disease.[6]  In secondary analyses, vancomycin 
was only associated with a decreased risk of mortality in those with severe disease and not in those with mild-
moderate disease (adjusted RR 0.91; 95% CI 0.72-1.14).[6]  Two randomized controlled trials have also 
compared metronidazole vs. vancomycin.[4, 5]  These studies, which did not use IDSA/SHEA criteria to define 
severity, have consistently demonstrated no difference in small subgroups of patients with mild CDI for 
recurrence and clinical cure. 
 
There are limitations to our retrospective study.  We were interested in assessing guideline concordant treatment 
thus required a CDI treatment duration of 10 to 14 days per guideline recommendations and that laboratory 
values be measured to assess disease severity.  Our results may not be generalizable to more mild cases that 
resolve sooner than 10 days or more severe or complicated cases that require treatment longer than 14 days or 
those in which SCr and WBC were not collected.  The VA population consists primarily of older White males and 
as such generalizability of this study to the general population may be limited. 
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Misclassification of outcomes and covariates may impact our results.  A priori, we chose to study 30-day CDI 
recurrence from the end of therapy, because most cases of CDI recur within 1-3 weeks after treatment.[10, 29, 
37-39]  Moreover, a consensus definition for CDI recurrence has not been established and most previous CDI 
clinical trials have assessed outcomes at 28-30 days post-treatment.[11]  Follow up time among studies 
assessing risk factors for CDI recurrence have ranged widely from 21-180 days from the previous CDI 
episode.[16]  Misclassification of CDI recurrence that occurred greater than 30 days after treatment is likely.  
However, the previous national VA study that compared vancomycin and metronidazole assessed for recurrence 
up to 56 days after the initial CDI diagnosis and similar to our findings found no difference between therapies on 
risk of recurrence.[6]  We only accounted for treatment and care in the VA system, therefore there is the potential 
that we may of misclassified recurrence in patients who received care for their recurrent episode outside the VA 
system. Our success and failure outcomes are composite outcomes that include mortality and recurrence and 
they have not been used previously.  We were not able to assess the resolution in CDI symptoms, so composite 
endpoints did not include treatment failure (continued diarrhea) which is another common poor outcome of 
CDI.[40]  As a consensus definition for CDI-attributable mortality is not established, we measured all-cause 
mortality.  It is possible that some of the deaths we observed were attributable, at least in part, to diseases other 
than CDI. 
 
In our observational comparative effectiveness analysis, since there was no randomization of patients to either 
metronidazole or vancomycin, confounding by indication is a chief concern.  During the study time period 
metronidazole was recommended first-line for mild-moderate disease and vancomycin was recommended for 
severe disease.[2]  Due to the differences in treatment recommendations, patients treated with vancomycin at 
baseline were inherently different than those treated with metronidazole, and at a higher baseline risk of poor 
outcomes.  We used restriction and propensity score matching in an attempt to reduce this confounding bias.  
Facility was included in the propensity score as there is no national VA policy for the treatment of CDI, and CDI 
treatment decisions could vary by facility.  While our propensity score included all observed confounders related 
to the use of metronidazole and vancomycin in our study population, there is the potential for residual 
confounding due to unknown factors and known but unmeasurable factors, such as cytokine responses to CDI.  
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Due to the small sample size in the propensity score matched analysis, random error may have impacted the 
observed results.   
 
Our findings among a national cohort of Veterans with an initial episode of mild CDI provide clinicians guidance 
on patients in whom metronidazole therapy may still be considered.  Age was the only predictor of success 
identified and among patients aged <65 years we found no difference between metronidazole compared with 
vancomycin on risk of 30-day all-cause mortality, CDI recurrence, or a composite of the two outcomes.  Other 
factors, such as a primary diagnosis of CDI on hospital admission, severe underlying comorbidities, and 
hypoalbuminemia were associated with failure and in patients with these conditions, alternative therapy with 
vancomycin or fidaxomicin should be considered.   
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Table 1. Baseline characteristics among a national cohort of Veterans with an initial episode of mild CDI 
treated with metronidazole with and without successful outcomes 
  Patients with success Patients without 
success (failure) 
 
n=3,282 % n=374 % p 
value 
Demographics      
Age < 65 years 1985 60.5 148 39.6 <0.001 
Male gender 2982 90.9 357 95.5 0.003 
White race 2494 76.0 281 75.1 0.714 
Hispanic ethnicity 148 4.5 16 4.3 0.838 
Married 1459 44.5 159 42.5 0.474 
Treatment setting      
    Acute care 401 12.2 109 29.1 <0.001 
    Long term care 84 2.6 21 5.6  
    Outpatient 2797 85.2 244 65.2  
Principal diagnosis of CDI on hospital 
admissiona 
92 2.8 31 8.3 <0.001 
Body mass index 30 or greater 1995 60.8 278 74.3 <0.001 
Albumin less than 1.5 1292 39.4 244 65.2 <0.001 
Hypervirulent CDI strain 190 5.8 22 5.9 0.942 
Charlson comorbidity score at the median or 
above 
2281 69.5 310 82.9 <0.001 
Elixhauser score at the median or above 2055 62.6 289 77.3 <0.001 
Comorbidities      
    Cardiopulmonary disease 1871 57.0 261 69.8 <0.001 
    Chronic renal disease 362 11.0 75 20.1 <0.001 
 19 
    Dementia 127 3.9 22 5.9 0.062 
    Diabetes   1108 33.8 130 34.8 0.699 
    Gastrointestinal/ nutritional disorder  1412 43.0 175 46.8 0.164 
    Liver disease  344 10.5 56 15.0 0.008 
    Malignancy 620 18.9 133 35.6 <0.001 
    Paralysis 137 4.2 26 7.0 0.014 
    Rheumatic disease 1263 38.5 167 44.7 0.021 
Current acute event or infection       
    Meningitis <5 
 
<5  0.277 
    Gram negative 136 4.1 27 7.2 0.006 
    Intestinal infection 769 23.4 148 39.6 <0.001 
    Acute bronchitis  12 0.4 <5  0.625 
    Pneumonia 121 3.7 35 9.4 <0.001 
    Septicemia 100 3.0 27 7.2 <0.001 
    Bacteremia  46 1.4 10 2.7 0.058 
    Shock 13 0.4 7 1.9 0.003 
    Skin and soft tissue 198 6.0 45 12.0 0.001 
    MRSA 18 0.5 8 2.1 0.003 
    Pseudomonas  20 0.6 6 1.6 0.043 
    Urinary tract infection 167 5.1 42 11.2 <0.001 
    Respiratory failure 64 2.0 36 9.6 <0.001 
    Acute renal failure 171 5.2 50 13.4 <0.001 
    Fever of unknown origin 76 2.3 6 1.6 0.379 
Previous acute event or infection      
    Meningitis 11 0.3 <5  1.00 
    Gram negative 155 4.7 26 7.0 0.060 
    Influenza 24 0.7 <5  0.752 
 20 
    Intestinal infection 883 26.9 173 46.3 <0.001 
    Acute bronchitis  177 5.4 12 3.2 0.071 
    Pneumonia 382 11.6 87 23.3 <0.001 
    Septicemia 246 7.5 62 16.6 <0.001 
    Bacteremia  118 3.6 22 5.9 0.029 
    Shock 40 1.2 16 4.3 <0.001 
    Skin and soft tissue 692 21.1 106 28.3 <0.001 
    MRSA 78 2.4 16 4.3 0.028 
    Pseudomonas  51 1.6 9 2.4 0.219 
    Urinary tract infection 515 15.7 93 24.9 <0.001 
    Respiratory failure 164 5.0 56 15.0 <0.001 
Healthcare exposures      
    Surgery, during CDI treatment 133 4.1 23 6.1 0.057 
    VA Hospitalization or long-term care, prior 
90 days 
1152 35.1 241 64.4 <0.001 
Medication exposures      
    Non-CDI antibiotic use, 30 days before or 
during CDI treatment 
2082 63.4 277 74.1 <0.001 
    Gastric acid suppressant use, 7 days before 
or during CDI treatment 
1123 34.2 189 50.5 <0.001 
    Immunosuppressant use, 7 days before or 
during CDI treatment 
192 5.9 61 16.3 <0.001 
    Probiotic use, 7 days before or during CDI 
treatment 
110 3.4 43 11.5 <0.001 
 
CDI= Clostridium difficile infection; IQR= interquartile range; SD= standard deviation 
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Success was defined as absence of death from any cause or CDI recurrence within 30 days from the end of 
treatment of the initial episode.  Patients with success were those who experienced success at day 30, and those 
without success (failures) were those who died or recurred within 30 days from end of treatment. 
 
aA principal diagnosis of CDI on hospital admission was compared to those without a principal diagnosis of CDI 
on hospital admission/ outpatients. 
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Table 2. Independent predictors of success and failure at 30 days post-CDI treatment with metronidazole 
monotherapy 
Predictor Adjusted Odds 
ratio  
Lower 95% 
confidence limit 
Upper 95% 
confidence limit 
Predictors of success - absence of mortality or CDI recurrence at day 30 post treatment (odds ratio > 
1) 
Age < 65 years  1.63 1.29 2.06 
Predictors of failure - mortality or CDI recurrence within 30 post treatment (odds ratio > 1) 
Probiotic exposure, 7 days prior or during 
CDI treatment 0.33 0.22 0.49 
Current respiratory failure 0.34 0.22 0.54 
VA hospital or long-term care exposure, 
90 days prior 0.52 0.41 0.67 
Hypoalbuminemiaa 0.53 0.42 0.68 
Principal diagnosis of CDI on hospital 
admission 0.54 0.34 0.85 
Malignancy  0.60 0.47 0.77 
Body mass index greater > 30 kg/m2 0.74 0.57 0.96 
Current intestinal infection 0.74 0.58 0.95 
CDI= Clostridium difficile infection 
 
The adjusted odds ratios are estimated from multivariable analysis of the data. The final multivariable 
unconditional logistic regression model included all variables in Table 2. Success was defined as absence of 
death from any cause or CDI recurrence within 30 days from the end of treatment of the initial episode.  Those 
with success were those who experienced success at day 30, and those without success (failures) were those 
who died or recurred within 30 days from end of treatment.  Thus, variables with an odds ratio greater than one 
were independent predictors of success, and those with an odds ratio less than one were predictors of failure. 
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aHypoalbuminemia was defined as an albumin level < 1.5 mg/dL as compared to level above or missing. 
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Table 3. Patient characteristics of patients aged 65 years or under with mild disease treated with 
metronidazole or vancomycin: Unmatched and matched cohorts  
 Unmatched cohort Matched cohort 
  Met 
(n=2,133)  
Van 
(n=118) 
 
  Met 
(n= 115) 
Van 
(n= 115) 
  
n % n % P 
value 
SB n % n % P 
value 
SB 
Demographics             
Age, years, median, 
IQR 
57 47-
62 
59 51-
64 
0.003 0.23 59 52-
63 
59 51-
64 
0.436 0.04 
Male gender 1853 86.9 105 89.0 0.507 0.06 101 87.8 103 89.6 0.677 0.05 
White race 1576 73.9 82 69.5 0.291 0.10 77 67 81 70.4 0.570 0.08 
Hispanic ethnicity 114 5.3 7 5.9 0.783 0.03 7 6.1 7 6.1 1.000 0.00 
Married 857 40.2 39 33.1 0.124 0.15 32 27.8 39 33.9 0.318 0.13 
Treatment setting             
    Acute care 207 9.7 34 28.8  0.50 38 33 33 28.7  0.09 
    Long term care 35 1.6 9 7.6  0.29 7 6.1 7 6.1  0.00 
    Outpatient 1891 88.7 75 63.6 <0.001 0.62 70 60.9 75 65.2 0.769 0.00 
Region             
    Midwest 532 24.9 19 16.1  0.22 15 14.3 18 17.1  0.05 
    Northeast 233 10.9 17 14.4  0.10 17 16.2 15 14.3  0.02 
    West 534 25.0 39 33.1  0.18 40 38.1 31 29.5  0.11 
    South 834 39.1 43 36.4 0.050 0.05 33 31.4 41 39.0 0.824 0.09 
Year             
    2010 247 11.6 3 2.5  0.36 5 4.3 3 2.6  0.10 
    2011 456 21.4 31 26.3  0.12 20 17.4 30 26.1  0.21 
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    2012 469 22.0 24 20.3  0.04 31 27 24 20.9  0.14 
    2013 439 20.6 30 25.4  0.12 28 24.3 28 24.3  0.00 
    2014 522 24.5 30 25.4 <0.028 0.02 31 27.0 30 26.1 0.492 0.00 
Principal diagnosis of 
CDI 
46 2.2 7 5.9 0.019 0.19 7 6.1 6 5.2 0.775 0.04 
Body mass index 30 or 
greater 
1190 55.8 85 72.0 <0.001 0.34 78 67.8 82 71.3 0.5667 0.08 
Albumin less than 1.5 754 35.3 70 59.3 <0.001 0.49 57 49.6 67 58.3 0.186 0.18 
Hypervirulent strain CDI  111 5.2 11 9.3 0.054 0.16 14 12.2 11 9.6 0.525 0.08 
 
Treatment duration, 
days, median (IQR) 
11 11-
11 
11 11-
12 
<0.001 0.31 11 11-
12 
11 11-
12 
0.792 0.03 
Charlson comorbidity 
score at the median or 
above 
1298 60.9 92 78.0 <0.001 0.38 84 73 89 77.4 0.445 0.10 
 
Elixhauser score at the 
median or above 
1215 57.0 90 76.3 <0.001 0.42 89 77.4 87 75.7 0.756 0.04 
 
Comorbidities             
    Cardiopulmonary 
disease 
983 46.1 73 61.9 <0.001 0.32 69 60 72 62.6 0.685 0.05 
    Chronic renal disease 173 8.1 14 11.9 0.150 0.13 9 7.8 13 11.3 0.370 0.12 
    Dementia 14 0.7 <5  0.203 0.10 <5  <5  1.00 0.06 
    Diabetes   625 29.3 34 28.8 0.910 0.01 33 28.7 34 29.6 0.885 0.02 
    Gastrointestinal/ 
nutritional disorder  
918 43.0 51 43.2 0.969 0.00 56 48.7 51 44.3 0.509 0.09 
    Liver disease  299 14.0 23 19.5 0.098 0.15 18 15.7 22 19.1 0.487 0.09 
    Malignancy 290 13.6 23 19.5 0.072 0.16 17 14.8 23 20 0.297 0.14 
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    Paralysis 82 3.8 9 7.6 0.052 0.16 7 6.1 9 7.8 0.604 0.07 
    Rheumatic disease 745 34.9 54 45.8 0.017 0.22 49 42.6 52 45.2 0.690 0.05 
Acute events or 
infections 
            
   Current acute renal 
failure 
83 3.9 9 7.6 0.055 0.16 6 5.2 9 7.8 0.423 0.11 
   Current fever of 
unknown origin 
52 2.4 <5  1.0 0.05 <5  <5  1.00 0.06 
    Current infection 651 30.5 62 52.5 <0.001 0.46 64 55.7 60 52.2 0.597 0.07 
    Current septicemia/ 
bacteremia / shock 
58 2.7 12 10.2 <0.001 0.31 7 6.1 11 9.6 0.326 0.13 
 
    Previous infection 1085 50.9 91 77.1 <0.001 0.57 90 78.3 88 76.5 0.753 0.04 
    Previous septicemia/ 
bacteremia / shock 
152 7.1 21 17.8 <0.001 0.33 18 15.7 20 17.4 0.723 0.05 
Healthcare exposures             
    Surgery, 30 days 
before or during CDI 
treatment 
79 3.7 10 8.5 0.024 0.20 10 8.7 9 7.8 0.811 0.03 
    VA Hospitalization or 
long-term care, prior 90 
days 
680 31.9 74 62.7 <0.001 0.65 72 62.6 72 62.6 1.00 0.00 
Medication exposures             
    Non-CDI antibiotic 
use, 30 days before or 
during CDI treatment 
1320 61.9 77 65.3 0.463 0.07 65 56.5 75 65.2 0.177 0.18 
    Gastric acid 
suppressant use, 7 days 
704 33.0 59 50.0 <0.001 0.35 57 49.6 58 50.4 0.895 0.02 
 27 
before or during CDI 
treatment 
    Immunosuppressant 
use, 7 days before or 
during CDI treatment 
103 4.8 16 13.6 <0.001 0.31 17 14.8 15 13 0.703 0.05 
    Probiotic use, 7 days 
before or during CDI 
treatment 
83 3.9 8 6.8 0.142 0.13 6 5.2 8 7 0.581 0.07 
SB = Standardized bias; CDI= Clostridium difficile infection; IQR= interquartile range; MET= metronidazole 
treatment; VAN= vancomycin treatment 
 
Data in the n % columns represent the number and percent, unless otherwise indicated.  
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Table 4. Unadjusted and propensity score matched hazard ratios for the effect of metronidazole versus 
vancomycin on outcomes among patients aged 65 years or under with an initial episode of mild CDI  
Clinical Outcome N event/ N 
met 
N event/ 
N van  
Unadjusted HR 
(95% CI) 
N / N 
met 
N events/ 
N van 
Matched HR 
(95% CI) 
All-cause mortality  33/2133 8/118 0.22 (0.10-0.48) 2/115 8/115 0.29 (0.06-
1.38) 
Recurrence  116/2133 15/118 0.42 (0.24-0.72) 8/115 14/115 0.62 (0.26-
1.49) 
Failure (mortality or 
recurrence) 
148/2133 23/118 0.33 (0.21-0.51) 10/115 22/115 0.50 (0.23-
1.07) 
CI = confidence interval; HR = hazard ratio; N= number; Van- = Vancomycin treated patients; Met = 
Metronidazole treated patients. 
Propensity score matched within 0.01 caliper. 
The propensity was derived from an unconditional logistic regression model controlling for age, region, Charlson 
comorbidity index, Elixhauser score, BMI, race, ethnicity, marital status, principal diagnosis of CDI, albumin, CDI 
treatment duration, gender, gastric acid suppressant use, antibiotic use, probiotic use, immunosuppressant use, 
VA long-term care or hospital exposure prior 90 days, cardiopulmonary disease, gastrointestinal /nutritional 
disorder, liver disease, diabetes, rheumatic disease, chronic renal disease, dementia, current acute renal failure, 
HIV, current fever, surgery, current sepsis/shock/ bacteremia, history of sepsis/shock/ bacteremia, history of 
infection, current infection, treatment setting, virulent strain.  
  
